



Apr 12th, 9:00 AM - 10:00 AM

The Safety and Efficacy of Drug Eluting Stents in Post-Heart Attack Recovery

Alex Hahn
Illinois Wesleyan University

Nicolas Shammass, Faculty Advisor
Midwest Cardiovascular Research Foundation

Follow this and additional works at: <https://digitalcommons.iwu.edu/jwprc>

Hahn, Alex and Shammass, Faculty Advisor, Nicolas, "The Safety and Efficacy of Drug Eluting Stents in Post-Heart Attack Recovery" (2008). *John Wesley Powell Student Research Conference*. 9.

<https://digitalcommons.iwu.edu/jwprc/2008/posters/9>

This Event is protected by copyright and/or related rights. It has been brought to you by Digital Commons @ IWU with permission from the rights-holder(s). You are free to use this material in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This material has been accepted for inclusion by faculty at Illinois Wesleyan University. For more information, please contact digitalcommons@iwu.edu.

©Copyright is owned by the author of this document.

Poster Presentation P17

**THE SAFETY AND EFFICACY OF DRUG ELUTING STENTS IN
POST-HEART ATTACK RECOVERY**

Alex Hahn, and Dr. Nicolas Shammass*

Biology Department, Illinois Wesleyan University
Midwest Cardiovascular Research Foundation

Recent concerns regarding the safety and efficacy of drug-eluting stents has led to further studies in post-heart attack recovery. Some researchers report an increased incidence of acute stent thrombosis (AST) leading to subsequent myocardial infarctions within the stented regions of the heart after anti-platelet drugs have been discontinued. The purpose of this study was to determine the safety and efficacy of Taxus® drug eluting stent and the correlation between the length of anti-platelet administration and further problems. The study population included patients who had an ST-elevated myocardial infarction within the past three years and were given drug eluting stents. Excluded patients included those who had bare metal stents, those who could not tolerate anti-platelet therapy, and those patients who had stents implanted prior to the study's beginning. Patients were interviewed and records were obtained from consenting individuals. Endpoints of death, incidence of acute stent thrombosis, and of recurrent myocardial infarction due to either target lesion revascularization or target vessel revascularization were determined. The results of this study will be used to evaluate any relationship recurrent heart attack, acute stent thrombosis and length of anti-platelet therapy.